Press

Acarix is a Scandinavia headquartered MedTech company marketing the CADScor®System – the innovative, non-invasive device designed to support a reliable and cost-effective rule-out of significant coronary artery disease (CAD) at the very first stage of the diagnostic pathway.

We are committed to bringing about a change in the early detection and assessment of coronary artery disease. Our press releases can be found below. For product images, press kits and other inquiries, please contact us. 

2021 11 09

MAR | Acarix accelerates US market entry with Proximo Medical as commercialization partner

MAR | Acarix accelerates US market entry with Proximo Medical as commercialization partner   PR Acarix Accelerates US Market eng PR Acarix Accelerates US Market swe            

2021 11 08

MAR | Acarix US expansion to be a major contributor to the company’s new financial and operational goals

MAR | Acarix US expansion to be a major contributor to the company’s new financial and operational goals   PR Acarix Guidance eng          

2021 11 05

Acarix Notice to EGM

Acarix Notice to EGM   Acarix Notice to EGM (eng) Acarix Notice to EGM (swe)          

2021 11 05

MAR | Acarix Rights Issue Launch Release

MAR | Acarix Rights Issue Launch Release   Rights Issue Launch Release (eng) Rights Issue Launch Release (swe)              

2021 10 27

Acarix granted US CPT reimbursement code for CADScor System

Acarix granted US CPT reimbursement code for CADScor System   Acarix PR CADScor ENG            

2021 09 07

New health economic study proves the value of CADScor® in coronary disease diagnostics

New health economic study proves the value of CADScor® in coronary disease diagnostics   Acarix PR CADScor HEOR publication SWE Acarix PR CADScor HEOR publication ENG            

2021 08 27

Initial Dan-NICAD II results presented today at ESC

Initial Dan-NICAD II results presented today at ESC   PR Acarix Dan-NICAD II abstract session SWE >> PR Acarix Dan-NICAD II abstract session ENG >>            

2021 08 23

Preliminary Dan-NICAD II results to be presented at ESC

Preliminary Dan-NICAD II results to be presented at ESC   PM Acarix Dan-NICAD II SWE PM Acarix Dan-NICAD II ENG            

2021 08 19

Acarix AB (publ) publishes Interim Report, January – June 2021

Acarix AB (publ) publishes Interim Report, January – June 2021     PR Acarix Q2 2021 eng >> PM Acarix Q2 2021 sv >> Acarix Q2 2021 eng >> Acarix Q2 2021 sv >>            

2021 04 20

Acarix publishes the annual report for 2020

Acarix Publishes the Annual Report for 2020   Today, Tuesday April 20, Acarix is publishing its Annual Report for 2020 on the company website www.acarix.com. The Annual Report is also attached to this press release.   PM_Acarix_Year-End_2020 eng Acarix_ÅR_...

2020 11 26

FDA identifies exclusive code for the CADScor®

FDA identifies exclusive code for the CADScor®System   After yesterday’s announcement and further analysis of the FDA approval,Acarix AB today announce that the company’s marketing approval of the CADScor®System in the US was granted under a new generic ty...

2020 10 19

Acarix changes Certified Advisor to Redeye

Acarix changes Certified Advisor to Redeye   Acarix AB (publ) announces today that the company has entered into anagreement with Redeye AB regarding the position as Certified Adviser.Redeye AB will take over as Certified Adviser on October 19, 2020. Acarix...

2020 09 29

Acarix carries out a directed issue of shares to guarantors in conjunction with the oversubscribed rights issue

Acarix carries out a directed issue of shares to guarantors in conjunction with the oversubscribed rights issue   Acarix AB (”Acarix” or the "Company") has, as previously announced, completed the rights issue ofshares amounting to approximately SEK 56 mill...

2020 09 28

Last day of trading in paid subscribed shares (Sw. BTA)

Last day of trading in paid subscribed shares (Sw. BTA)   Last day of trading in subscribed paid shares ("BTA") in Acarix AB ("Acarix" or the “Company") willbe Thursday the 1 October 2020 and stop day will be Monday the 5 October 2020.In the rights issue, ...

2020 09 11

Acarix announce final outcome in oversubscribed rights issue

Acarix announce final outcome in oversubscribed rights issue   Acarix AB ("Acarix" or the "Company") has completed the new share issue of a maximum of86,156,738 shares with preferential rights for the Company's existing shareholders, which wasresolved by t...

2020 09 09

MAR | Acarix announces preliminary outcome in oversubscribed rights issue

The board of directors of Acarix AB ("Acarix" or the "Company") has, subject to the subsequent approval of an Extraordinary General Meeting, resolved to carry out a new share issue of a maximum of 86,156,738 shares with preferential rights for the Company'...

2020 09 03

Acarix publishes a supplement to the prospectus

Acarix publishes a supplement to the prospectus The board of directors of Acarix AB ("Acarix" or the "Company") has prepared a supplement to theprospectus regarding invitation to acquire shares in the approved preferential rights issue in Acarixwhich was a...

2020 08 31

Acarix VD Per Persson presenterade på Redeye

Acarix VD Per Persson presenterade på Redeye   Vid en investerarpresentation på Redeye den 25 augusti utvecklade Acarixsvd Per Persson hur han ser på bolaget och den pågåendeföreträdesemissionen. Han gav också en uppdatering kring bolagetsframsteg. Acarix_...

2020 08 20

Acarix publishes prospectus in connection with rights issue of approximately SEK 56 million

Acarix publishes prospectus in connectionwith rights issue of approximately SEK 56 million     Acarix_PR_publication_of_prospectus (1) Acarix_PM_offentliggörande_prospekt

2020 08 07

Acarix Publishes Interim Report, January – June, 2020

Acarix AB (publ) publishes Interim Report, January – June 2020 For us and for many other companies, the pandemic and global uncertainty have caused delays in someprioritized projects. However, in combination with a dynamic capital market this has created a...

2020 07 15

MAR | Acarix decides on a guaranteed rights issue of approximately SEK 56 million

The board of directors of Acarix AB ("Acarix" or the "Company") has, subject to the subsequent approval of an Extraordinary General Meeting, resolved to carry out a new share issue of a maximum of 86,156,738 shares with preferential rights for the Company'...

2020 02 20

MAR | Acarix Year-End Report 2019

Press release MAR | Successful rights issue enables increasedfocus on strategic initiatives   The fourth quarter of 2019 was eventful, and we had the opportunity to see progressin several areas. Importantly, we closed a rights issue of SEK 43 million, befo...

2020 02 18

First patient enrolled in the new clinical study FILTER-SCAD targeting 2,000 patients

Acarix AB (publ) today announced the initiation of the randomized, multicenter clinical study FILTER-SCAD to examine the cost effectiveness and safety of adding the CADScor®System as a rule-out test in patients referred with symptoms suggestive of stable c...

2019 11 14

MAR | Interim Report, January – September 2019

Acarix finalized a rights issue to finance further market expansion

2019 10 30

MAR | Acarix announce final outcome in rights issue

Press release MAR |Acarix announce final outcome in rights issue   Acarix AB ("Acarix" or the "Company") has completed the new share issue of a maximum of34,541,064 shares with preferential rights for the Company's existing shareholders, which wasresolved ...

2019 09 25

MAR | Acarix carries out a rights issue of approximately SEK 51.8 million to finance an increased market expansion

The board of directors of Acarix AB ("Acarix" or the "Company") has today, pursuant to the authorization granted by the extra general meeting on 16 August 2019, resolved to carry out a new share issue of a maximum of 34,541,064 shares with preferential rig...

2019 08 16

MAR | Announcement from Acarix’s extra general meeting

MAR | Announcement from Acarix's extra general meeting The extra general meeting ("EGM") of Acarix AB ("Acarix" or the "Company") was held today on 16 August 2019 and the following resolutions were passed by the meeting. Announcement from Acarix's extra ge...

2019 08 06

MAR | Interim Report January – June 2019

MAR | Interim Report January – June 2019   ”With CADScor®System we have a fantastic opportunity to revolutionize the way the healthcare system handles patients with suspected coronary artery disease, CAD. In our daily work at Acarix, we see that the need f...

2019 05 20

MAR | Announcement from Acarix’s annual general meeting May 2019

MAR | Announcement from Acarix’s annual general meeting May 2019   May 16, 2019 The annual general meeting (“AGM”) of Acarix AB (“Acarix” or the “Company”) was held today on 16 May 2019 and the following resolutions were passed by the meeting. Adoption of ...

2019 05 16

MAR | Interim report, January – March 2019

MAR | Interim report, January – March 2019 May 16, 2019   ”After almost a year at Acarix, I am truly inspired by the opportunities our products offer to revolutionize heart diagnosis. We participate actively in congresses and scientific conferences and...

2019 04 25

MAR | Acarix publishes annual report for 2018

MAR | Acarix publishes annual report for 2018   April 25, 2019 Today, Thursday April 25, Acarix is publishing its Annual Report for 2018 on the company website www.acarix.com. The Annual Report is found here. For further information, please contact:Per Per...

2019 02 20

MAR | Acarix Year-End Report 2018

Press release MAR | Market dynamics favourable for CADScor®System, addressing the challenges of the global healthcare market   ”After six months at Acarix, I clearly see our market evolving and a growing opportunity for our products aimed at revolutioniz...

2019 01 15

MAR | Acarix adapts pathway for German reimbursement

MAR | Submission of new dossier by the end of February 2019   Jan 15, 2019 Acarix AB (publ) (ACARIX: FN Stockholm) today announced it will file for German reimbursementdirectly with the Federal Joint Committee (G-BA) for its CADScorSystem®. Previously, Aca...

2018 11 14

MAR | Interim Report, January – September 2018

MAR | Interim Report, January – September 2018   Nov 14, 2018 ”During the quarter we proudly reported that Kristianstad Central Hospital in Sweden evaluated the CADScor®System with a positive outcome. Due to the good result the hospital´s clinical manageme...

2018 11 13

MAR | Acarix (FN STO: ACARIX) today announced that the board of directors has appointed Per Persson to Chief Executive Officer

MAR | Acarix (FN STO: ACARIX) today announced that the board of directors has appointed Per Persson to Chief Executive Officer Nov 13, 2018 Per Persson comes directly from the role as Chief Commercial Officer of Acarix. Christian Lindholm, who has served ...

2018 08 21

MAR | Interim Report, January – June 2018

MAR | Interim Report, January – June 2018   Acarix gains traction in key markets providing physicians and patients new opportunities ”Since the inception of Acarix, the company has been fully committed to developing a reliable, noninvasive and radiation-fr...

2018 05 23

MAR | Interim, Januari – March 2018

MAR | Interim, Januari – March 2018   CADScor®System launched in key markets   “Acarix introduced the CADScor®System on the German, Swedish and Danish markets 11 months ago, in June 2017. The introduction was made without general reimbursement, which is on...

2018 04 23

MAR | Annual report 2017

MAR | Annual report 2017   Today, Monday April 23, Acarix is publishing its Annual Report for 2017. For further information please contact:Christian Lindholm, Interim CEOE-mail: secli@acarix.comPhone: +46 705 118333 This information is information that Aca...

2018 02 26

MAR | Year-end Report January-December 2017

MAR | Year-end Report January-December 2017   CADScor®System launched in key markets ”In 2017, we achieved historic milestones in Acarix – most noticeably the receipt of our first commercial order for CADScor®System in June and thus a confirmation of the c...